secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001601485-24-000074
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics Q3 2024 net loss $18.8M, cash $26M; AMPLIFY-7P enrollment on track
--------------------------------------------------------------------------------

- Net loss $18.8M ($1.39 per share) vs $10.7M ($1.27) YoY; includes $8.5M non-cash warrant liability change.
- Cash and cash equivalents $26.0M as of Sept 30, 2024; operational changes expected to fund into Q2 2025.
- AMPLIFY-7P Phase 2 randomized study enrollment completion expected Q4 2024; interim DFS analysis H1 2025.
- SITC poster showed durable T cell responses and antigen spreading in KRAS mutant tumors; ESMO oral presentation in Dec 2024.
- R&D expense $7.2M, G&A $3.1M; $1.5M grant and $20M convertible notes closed in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/0001601485-24-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/angn-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer